Cite
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure
MLA
Elio M. Vinci, et al. “Randomized Phase II Study of Danusertib in Patients with Metastatic Castration-Resistant Prostate Cancer after Docetaxel Failure.” BJU International, vol. 111, Aug. 2012, pp. 44–52. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........91696ec7bbe40ab7c56215ea468c48f8&authtype=sso&custid=ns315887.
APA
Elio M. Vinci, Armando Santoro, Giordano Vitali, Mariangela Mariani, Rossana Berardi, Scott T. Tagawa, Hielke J. Meulenbeld, Ronald de Wit, Luigi Dogliotti, Jean P. Bleuse, Cora N. Sternberg, Federico Cappuzzo, Eric Raymond, Anna Petroccione, & M. G. Jannuzzo. (2012). Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU International, 111, 44–52.
Chicago
Elio M. Vinci, Armando Santoro, Giordano Vitali, Mariangela Mariani, Rossana Berardi, Scott T. Tagawa, Hielke J. Meulenbeld, et al. 2012. “Randomized Phase II Study of Danusertib in Patients with Metastatic Castration-Resistant Prostate Cancer after Docetaxel Failure.” BJU International 111 (August): 44–52. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........91696ec7bbe40ab7c56215ea468c48f8&authtype=sso&custid=ns315887.